Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Key Points

• CEO Amit Kumar purchased 5,000 Anixa Biosciences shares at an average price of $2.76, investing $13,800 and increasing his direct ownership to 662,000 shares. This follows several other insider purchases in recent months.
• Anixa shares opened at $2.75, down 2.8%, with a market capitalization of approximately $93.6 million. The company reported quarterly EPS of $(0.08), in line with analyst expectations.
• Analyst sentiment is mixed, with an overall “Hold” rating and a $10 average price target; institutional investors own about 29.1% of the stock.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 5,000 shares of the business's stock in a transaction dated Thursday, September 10th. The shares were purchased at an average price of $2.76 per share, with a total value of $13,800.00. Following the acquisition, the chief executive officer directly owned 662,000 shares in the company, valued at approximately $1,827,120. The trade was a 0.76% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $15,200.00.

Anixa Biosciences Stock Down 2.8%

Anixa Biosciences stock opened at $2.75 on Friday. The company's 50 day moving average is $3.34 and its two-hundred day moving average is $2.99. The firm has a market cap of $93.56 million, a PE ratio of -8.59 and a beta of 0.51. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). On average, equities research analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently added to or reduced their stakes in ANIX. BlackRock Inc. acquired a new stake in shares of Anixa Biosciences during the second quarter worth $559,000. GSA Capital Partners LLP acquired a new position in Anixa Biosciences in the 2nd quarter valued at $329,000. 683 Capital Management LLC purchased a new position in Anixa Biosciences during the 4th quarter worth $355,000. ExodusPoint Capital Management LP purchased a new position in Anixa Biosciences during the 4th quarter worth $293,000. Finally, Susquehanna International Group LLP lifted its stake in shares of Anixa Biosciences by 378.4% in the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company's stock worth $265,000 after acquiring an additional 63,584 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ANIX shares. Weiss Ratings downgraded shares of Anixa Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, September 3rd. Zacks Research cut Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. HC Wainwright reissued a "buy" rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen upgraded shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 20th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $10.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.